Micromet (MITI) 11.00 0.00

Micromet, Inc.
(MITI) 11.00 0.00

Last Trade:	10.99	Day Range:	10.99 - 10.99
Trade Time:	Mar 07	52wk Range:	4.13 - 11.00
Prev. Close:	10.99	Market Cap:	1.05B
Open:	10.99	Div Yield:	0
Volume:	0	PE:
EPS:	-0.81

The Latest On MITI

Amgen Completes Tender Offer for Outstanding Shares of Micromet 3/7/12 9:03am

Amgen Announces Initial Results of Tender Offer for Outstanding Shares of Micromet and Commencement of Subsequent Offering 3/2/12 9:01am

Amgen and Micromet Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Micromet 2/15/12 10:26am

Verastem IPO Launch Captures Investors Attention 2/1/12 11:54pm

Momentum Trading: These 6 Stocks Are Up More Than 50% Already in 2012 1/27/12 4:50pm

Needham Downgrades Micromet to Hold 1/27/12 10:21am

Benzinga's M&A Chatter for Thursday January 26, 2012 1/26/12 7:24pm

Ladenburg Thalmann Downgrades Micromet to Neutral 1/26/12 3:26pm

Piper Jaffray Downgrades Micromet to Neutral 1/26/12 1:15pm

Micromet Up 33% After Acquisition Announcement 1/26/12 9:53am

Amgen to Acquire Micromet for $11 per Share Totaling $1.16B 1/26/12 9:02am

Micromet Signs CRADA with National Cancer Institute to Expand Development of Blinatumomab 1/9/12 9:11am

Amgen Completes Tender Offer for Outstanding Shares of Micromet 3/7/12

Amgen Announces Initial Results of Tender Offer for Outstanding Shares of Micromet and Commencement of Subsequent Offering 3/2/12

Amgen and Micromet Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Micromet 2/15/12

Verastem IPO Launch Captures Investors Attention 2/1/12

Momentum Trading: These 6 Stocks Are Up More Than 50% Already in 2012 1/27/12

Needham Downgrades Micromet to Hold 1/27/12

Benzinga's M&A Chatter for Thursday January 26, 2012 1/26/12

Ladenburg Thalmann Downgrades Micromet to Neutral 1/26/12

Piper Jaffray Downgrades Micromet to Neutral 1/26/12

Micromet Up 33% After Acquisition Announcement 1/26/12

Amgen to Acquire Micromet for $11 per Share Totaling $1.16B 1/26/12

Micromet Signs CRADA with National Cancer Institute to Expand Development of Blinatumomab 1/9/12

Verastem IPO Launch Captures Investors Attention 2/1/12

Momentum Trading: These 6 Stocks Are Up More Than 50% Already in 2012 1/27/12

Benzinga's M&A Chatter for Thursday January 26, 2012 1/26/12

Weekly Homework: In Search Of The Santa Claus Rally (w/ Economic Calendar & Stock Radar) 12/12/11

Promising Leukemia Drug Boosts Micromet 6/11/11

Top Percentage Gainers and Losers as of 2pm 06/10/11 6/10/11

Top Percentage Gainers and Losers as of 12pm 06/10/11 6/10/11

Mad Money Lightning Round OT: Cramer Likes ETP And GG (MITI, AT, ETP, NEM, GG, NG) 3/29/11

Benzinga’s Top Downgrades (MITI, VCLK, NILE, PCYC, CSTR) 2/12/10

Benzinga’s Top Pre- Market Gainers (TSTC, CTCM, SEED, GSIT, MITI, NVAX, NVMI, SPLS) 12/1/09

Needham Downgrades Micromet to Hold 1/27/12

Ladenburg Thalmann Downgrades Micromet to Neutral 1/26/12

Piper Jaffray Downgrades Micromet to Neutral 1/26/12

Ladenburg Thalmann Maintains Buy Rating and $7.50 PT on Micromet 10/14/11

UPDATE: Goldman Sachs Initiates Coverage on Micromet 8/17/11

Goldman Sachs Initiates Micromet At Neutral, $5 PT 8/17/11

Edison Comments on Micromet 7/13/11

Benzinga's Top Upgrades (CHTR, MITI, WPRT, BCS) 4/6/11

RBC Capital Upgrades Micromet To Outperform, $8 PT 4/6/11

Piper Jaffray's Favorite Antibody Plays (SGEN, MITI, REGN) 1/5/11

Piper Jaffray Reiterates Overweight Rating on Micromet (MITI) 11/22/10

Benzinga’s Top Downgrades (MITI, VCLK, NILE, PCYC, CSTR) 2/12/10

Trade MITI
NOW!

Partner Headlines

Micromet Inc. Reports Operating Results (10-K) 3/2/12

Amgen a Step Closer to Micromet - Analyst Blog 2/22/12

Amgen Upped to Outperform - Analyst Blog 2/8/12

Amgen Misses; 2012 Outlook Strong - Analyst Blog 1/27/12

Amgen Acquires Micromet for $1.16 Billion 1/26/12

Micromet Stays Neutral - Analyst Blog 12/8/11

Micromet Begins New Trial - Analyst Blog 12/5/11

Risk-Reward Balanced at Micromet - Analyst Blog 9/12/11

Micromet Loss Better of Est, Rev Up - Analyst Blog 8/8/11

MITI Strikes Cancer Deal with Amgen - Analyst Blog 7/12/11

Biotech Stock Mailbag: Transcept Pharma 7/8/11

Neutral on Micromet - Analyst Blog 7/6/11

Press Releases

Amgen Completes Tender Offer for Outstanding Shares of Micromet, Inc. 3/7/12 Newswire

Amgen Announces Initial Results of Tender Offer for Outstanding Shares of Micromet, Inc. and Commencement of Subsequent Offering Period 3/2/12 Newswire

Amgen and Micromet Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Micromet 2/15/12 Newswire

Buyout Offer for Micromet Triggers Shareholder-Claim Investigation by Goldfarb LLP Securities Attorneys 2/3/12 Newswire

Bull & Lifshitz, LLP Announces Investigation of Micromet, Inc. 2/2/12 Newswire

Faruqi & Faruqi, LLP Announces Investigation of Micromet, Inc. 1/28/12 Business Wire

The Law Firm of Weiss & Lurie Investigates Micromet, Inc. 1/27/12 Business Wire

Harwood Feffer LLP Announces Investigation of Micromet Inc. 1/27/12 Business Wire

Holzer Holzer & Fistel, LLC Announces Investigation into the Proposed Buyout of Micromet, Inc. 1/27/12 Business Wire

Robbins Umeda LLP Announces an Investigation of Micromet, Inc. 1/27/12 Business Wire

MITI, ENMD and IRSN are the Stocks to Watch for January 27th from OTCPicks.com 1/27/12 Emailwire

Get the latest MITI stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Micromet, Inc. stock price.

Micromet, Inc. by YCharts

Micromet (MITI) 11.00 0.00

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On MITI

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social